Efficacy and Safety Analysis of First-Line ABCP Therapy in Advanced SMARCA4-Mutated NSCLC

NCT07093762 · tracked via the Priya Life Science China tracker

Sponsor

Fuzhou General Hospital

Phase

Observational

Started

2025-08-20

Last updated

2025-07-30

Condition(s) studied

Non Small Cell Lung Cancer

Investigational drug(s) / intervention(s)

Atezolizumab+Bevacizumab+Carboplatin+PaclitaxelAll Atezolizumab trials (176) →All Bevacizumab trials (435) →All Carboplatin trials (591) →All Paclitaxel trials (423) →

Atezolizumab+Bevacizumab+Carboplatin+Paclitaxel: Atezolizumab: 1200 mg IV every 3 weeks; Bevacizumab: 15 mg/kg IV every 3 weeks; Carboplatin: AUC 5 IV every 3 weeks; Paclitaxel: 175 mg/m² IV every 3 weeks. Treatment cycles: After 4-6 cycles, continue Atezolizumab + Bevacizumab as maintenance therapy until disease progression or unacceptable toxicity.

Study summary

SMARCA4 mutation is clinically known to be an independent poor prognostic factor. Both TCGA and the investigators institution's preliminary research indicate that the median overall survival (OS) of mutated patients is significantly shorter than that of wild-type patients (32 months vs. 157.7 months, respectively, P=0.001); it is associated with chemotherapy/immunotherapy resistance, rapid progression, and poor prognosis (OS\<12 months). Current standard first-line treatments (such as platinum-based chemotherapy ± immunotherapy) have limited efficacy in SMARCA4-mutated patients (ORR\<30%, PFS\<4 months). Additionally, NapsinA-positive expression can improve the survival of mutated patients (median OS: 32 months vs. 15 months, P=0.033), but this effect exists only in the SMARCA4-mutated group.

The ABCP regimen has a synergistic mechanism: Atezolizumab (anti-PD-L1): reverses the immunosuppressive microenvironment; Bevacizumab (anti-VEGF): inhibits angiogenesis and enhances T-cell infiltration; Platinum + Paclitaxel: directly kill tumor cells and release neoantigens. Therefore, the investigators preset that SMARCA4 mutation may affect chemotherapy/immunotherapy response through epigenetic regulation, and its value as a predictive biomarker needs to be validated. Hence, the purpose of this study is to observe and explore the efficacy and safety of first-line ABCP four-drug combination therapy in patients with advanced SMARCA4-mutated non-small cell lung cancer.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: 1. Patients with pathologically confirmed NSCLC, meeting the following criteria based on the IASLC 9th Edition Lung Cancer TNM Staging System (International Association for the Study of Lung Cancer/Union for International Cancer Control): Histologically or cytologically confirmed unresectable locally advanced (Stage IIIB/IIIC) disease not amenable to curative-intent concurrent chemoradiotherapy, metastatic, or recurrent (Stage IV) non-squamous NSCLC; 2. Confirmed SMARCA4 mutation (verified by NGS testing); 3. ECOG performance status 0-1, with no prior systemic anticancer therapy; 4. Absence of driver gene mutations (e.g., EGFR, ALK, ROS1); 5. Patients capable of providing sufficient blood samples (detailed in sample requirements) and complete baseline clinical data, including: age, gender, smoking history, family history, lesion location(s), lesion size(s), number of lesions, tumor markers, pathological indicators, treatment records, and re-examination/follow-up information; 6. Voluntary participation with signed informed consent form, willingness to undergo follow-up assessments and provide treatment process details, efficacy data, and prognostic information, with commitment to complete the entire study. Exclusion Criteria: * (1) Active autoimmune diseases or interstitial lung disease; (2) Bleeding tendency or contraindications to Bevacizumab.

Primary outcome measure(s)

Objective Response Rate — through study completion, an average of 1 year
Objective Response Rate (ORR): Assessed according to RECIST v1.1 criteria to evaluate the antitumor activity of the ABCP regimen.
Progression-Free Survival — through study completion, an average of 1 year
Progression-Free Survival (PFS): Defined as the time from enrollment to disease progression or death.

Trial sites (1)

Facility	City	Region	Status
The 900th Hospital of the Joint Logistic Support Force, PLA, Fuzhou, Fujian, China, 350025	Fuzhou	China

More Fuzhou General Hospital trials in China

SERS-Based Serum Molecular Spectral Detection of Invasive Lung Cancer Starting soon

Induction Tislelizumab Combined With Chemotherapy Followed by Definitive Chemoradiotherapy in the Treatment of Locally Unresectable Esophageal Squamous Cell Carcinoma Recruiting

SERS-Based Serum Molecular Spectral Screening for Hematogenous Metastasis Starting soon

SERS-Based Serum Molecular Spectral Screening for Benign and Malignant Pulmonary Proliferative Nodules Starting soon

Other trials for the same condition

Surufatinib Combined With Toripalimab and Chemotherapy in the Treatment of Non-Small Cell Lung Cancer Active, not recruiting

An Observational Clinical Study of Stereotactic Radiotherapy for Advanced Non-Small Cell Lung Cancer With Stable Disease After PD-1 Inhibitor Treatment Recruiting

Multiple Omics Sequencing Technologies in Predicting the Efficacy and Monitoring the Recurrence of Non-Small Cell Lung Cancer Recruiting

Stereotactic Body Radiation Therapy for Spinal Metastases in Favorite Tumors Recruiting

A Clinical Study of LM103 Injection in the Treatment of Advanced Solid Tumors Recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07093762 on ClinicalTrials.gov ↗ ← All trials in China